signs of active inflammation were not found. Based on etiological agent all pts were divided into 3 groups: Group I—with bacterial infection (5 pts (15%)), Group II—with viral infection (11 pts (35%)), Group III—with mixed bacterial and viral infection (16 pts (50%)). Rapid nodule regression was strongly associated with elevated ASO titers at baseline ($p=0.02$) and presence of bacterial agents ($p=0.0007$). Recurrences were documented in 13 pts (40.6%), among them 7 (54.1%) cases were triggered by ARVI/common frigoris, 2 (15.3%) cases—by stress, 2 (15.3%) cases—by non-compliance or treatment failure, 2 (15.3%)—by exacerbation of chronic tonsillitis. There was no statistically significant association between intake of individual medications and full reversal of the disease. There was 1 (8% from total number) recurrence episode in Group I, 7 (54%) episodes—in Group II, and 5 (38%)—in Group III. Recurrent disease inversely correlated with affected surface area (affected leg surfaces) ($p=0.03$). Pts who achieved nodular regression had elevated ASO at EN onset ($p=0.00008$), in contrast to pts with recurrent disease.

Conclusions: Streptococcus spp (56.3%) seem to be the leading cause of EN associated with infection. Lab verification of streptococcal infection with subsequent adequate antibacterial therapy facilitates the favourable clinical course of EN.

Acknowledgements: The study had no sponsorship.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.2278

AB1363 ARE YOU ABLE TO CUT YOUR MEAT? – EXPLORING THE CHALLENGES DURING THE CULTURAL ADAPTATION OF THE HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI) INTO 130 LANGUAGES

C. Acquadro¹, C. Anfray², P. Bindi², V. Uzun³. ¹Thought Leadership, Mapi, an ICON plc Company; ²Author Collaboration Unit, Mapi Research Trust; ³Language Services, Mapi, an ICON plc Company, Lyon, France

Background: The disability assessment component of the Health Assessment Questionnaire, the HAQ-DI,¹ developed in US English, assesses a patient's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in eight categories of functioning which represent a comprehensive set of functional activities – dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The stem of each item asks over the past week "Are you able to ..." perform a particular task. The patient's responses are made on a scale from zero (no disability) to three (completely disabled).

Objectives: To explore the challenges faced during the cultural adaptation of the HAQ-DI, focusing on one simple task, i.e., "Are you able to cut your meat?" in the eating category.

Methods: The archives of Mapi Language Services were searched and 130 translations were retrieved, representing 13 language families. The translation methods followed either the standard linguistic validation process [i.e., conceptual analysis, dual translation process (forward, backward translation into English), test with patients and clinician review] or the adjusted process in case of countries using national variants of the same language (i.e., Australian English or English used in India).²

Results: In most of the target languages, cutting a whole piece of meat presented in one plate was not a cultural issue. However, in vegetarian-driven cultures or countries where cutting meat was performed while cooking, the item had to be adapted and changed to comply both with the local culture and the concept explored by the item (i.e., fine movement of the upper extremity). For instance, an equivalent of "to cut meat while cooking" was chosen in Korean; "to cut meat (when eating or preparing food)," in Bahasa (Indonesia); "to cut raw vegetables," in Gujarati (India); or "make bite size pieces of your food (e.g., chapatis)" in English for India.

Conclusions: The close collaboration between the developer and the translation teams was essential in finding appropriate conceptual equivalents of the simple task of cutting meat in 13 different language families.

REFERENCES:

- [1] Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. *Health Qual Life Outcomes*. 2003 Jun 9;1:20.
- [2] Mear I, Giroudet C. Chapter 1: Linguistic Validation Procedures. In: Acquadro C, Conway K, Giroudet C, Mear I, editors. *Linguistic Validation Manual for Health Outcome Assessments*. Lyon, France: Mapi Institute; 2012. p. 15–117.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4591

AB1364 ADAPTATION AND VALIDATION OF THE RHEUMATOID ARTHRITIS QUALITY OF LIFE (RAQOL) SCALE FOR PORTUGAL

F. Fernandes¹, C. Duarte^{1,2}, N. Madeira³, P. Pinto⁴, C. Furtado⁵, C. Ribeiro⁶, M. Couto⁷, D. Santos Faria⁸, T. Rocha⁹, R. Freitas¹⁰, A.R. Cunha¹¹, A. Heaney¹², S. McKenna¹², J.A. Pereira da Silva^{1,2}. ¹Faculdade de Medicina da Universidade de Coimbra; ²Centro Hospitalar Universitário de Coimbra, Coimbra; ³Instituto Português de Reumatologia, Lisboa; ⁴Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia; ⁵Hospital do Divino Espírito Santo, S. Miguel; ⁶Centro Hospitalar Universitário do Algarve, Faro; ⁷Centro Hospitalar Tondela-Viseu, Viseu; ⁸Unidade Local de Saúde Alto Minho, Ponte de Lima; ⁹Centro Hospitalar São João, Porto; ¹⁰Hospital Garcia de Orta, Almada; ¹¹Centro Hospitalar Baixo Vouga, Aveiro, Portugal; ¹²Galen Research, London, UK

Background: Rheumatoid Arthritis (RA) is a chronic inflammatory disease that has a major impact on patients' quality of life. The Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) is a patient-centric outcome measure, specific to RA. The measure has not previously been available for use with Portuguese RA patients.

Objectives: To produce a Portuguese version of the RAQoL that is acceptable to Portuguese patients and demonstrates sound psychometric properties.

Methods: The dual panel methodology was used to translate the UK RAQoL into Portuguese. This involved conducting a bilingual panel (providing the initial translation into Portuguese) followed by a lay panel (where items are assessed for comprehension and acceptability). Cognitive debriefing interviews were conducted with Portuguese RA patients to determine the face and content validity of the translated scale. A large-scale postal validation survey was carried out to establish the psychometric properties of the Portuguese RAQoL. The measure was administered on two occasions to RA patients, alongside a comparator instrument – the Nottingham Health Profile (NHP).

Internal consistency was assessed using Cronbach's alpha coefficient. Spearman's Rank correlation coefficient was employed to assess test-retest reliability. Convergent validity was tested by correlating RAQoL scores with those on the NHP sections. Known group validity was assessed using non-parametric tests for independent samples. This involved determining the ability of the RAQoL to distinguish between patients that differed according to their self-perceived severity of RA and general health.

Results: The translation panels produced a Portuguese version of the RAQoL that was easily understood and considered natural by native speakers. Interviewees considered the new language version to be relevant and appropriate. One hundred and seventy-eight RA patients (82% female) took part in the postal validation survey with a mean age of 56.6 (range 25 to 79) years. The Portuguese RAQoL demonstrated excellent internal consistency (Cronbach's $\alpha=0.95$) and test-retest reliability ($r=0.92$), indicating that the measure produces low levels of random measurement error.

RAQoL scores correlated most strongly with scores on the NHP Physical mobility scale ($r=0.77$) and showed moderately strong correlations with the Emotional reactions, Pain and Energy level section scores.

Non-parametric tests for independent samples demonstrated significant differences in RAQoL scores between patients who differed according to their self-perceived RA severity ($p<0.001$) and general health ($p<0.001$).

Conclusions: The Portuguese version of the RAQoL was found to be a comprehensive, reliable and valid questionnaire. The new language version is recommended for use in routine clinical practice and for research purposes, to assess quality of life in Portuguese RA patients.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5989

AB1365 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS/LUPUS NEPHRITIS

C. Fang, T. Luo, L. Lin. Second Affiliated Hospital of Fujian Medical University, Quanzhou, China

Background: SLE patients have a tendency of accelerated atherosclerosis (AS) which can only partly be explained by traditional risk factors for cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9), which is a protease associated with cardiovascular risk that regulates both cholesterol metabolism and inflammatory reaction, had been regarded as a highly promising therapeutic target for cardiovascular disease.¹ Recent study had demonstrated that SLE patients with lupus nephritis (LN) had much higher risk of atherosclerosis.²

Objectives: To assess serum PCSK9 concentrations and the possible factors linked with PCSK9 variation in SLE/LN patients.

Methods: 47 SLE patients and 30 healthy controls were included. Traditional cardiovascular risk factors were compared. According to cIMT, SLE patients were divided into two subgroups (SLE-AS subgroup and SLE-NonAS subgroup, cut-off point is 1.0 mm). PCSK9 concentrations were compared between: ¹SLE patients

and controls;²SLE-AS subgroup and SLE-NonAS subgroup;³SLE patients with and without lupus nephritis(LN). The correlational analyses between PCSK9 levels and disease parameters were undergone.

Results: The differences of lipids parameters, body mass index (BMI), uric acid (UA) between SLE group and controls had no statistical significance. Even so, the ratio of cIMT thickening were higher in SLE patients, when compared with healthy controls (23.40% versus 6.67%, $p=0.05$). Serum PCSK9 levels were also significantly elevated in SLE patients than controls (median of PCSK9 level: 390.53 ng/ml versus 292.44 ng/ml, $p<0.05$). Patients in SLE-AS subgroup had even higher PCSK9 and C-reactive protein(CRP) levels than those in SLE-NonAS subgroup (median of PCSK9 level: 516.41 ng/ml versus 364.47 ng/ml, $p<0.05$; median of CRP level: 4.56 mg/L versus 1.05 mg/L, $p<0.01$) (figure 1). PCSK9 levels correlated with CRP levels, but not with age, disease activity, lipids characteristics, BMI or UA levels, particularly in female patients (table 1). Despite of no statistical significance, the ratio of lupus nephritis were higher in SLE-AS subgroup than those in SLE-NonAS subgroup (63.64% versus 44.44%, $p>0.05$). SLE patients with LN had higher PCSK9 concentrations than those without LN evidence(509.53 $\pm$ 131.69 ng/ml versus 332.02 $\pm$ 92.72 ng/ml, $p<0.001$).

Abstract AB1365 – Table 1. Correlational analysis of PCSK9 levels and disease parameters in SLE patients.

Variables	r_s	p -value
Age(years)	-0.014	0.927
SLEDAI	0.092	0.539
BMI(kg/m ²)	-0.120	0.420
Cholesterol(mmol/l)	-0.012	0.935
LDL cholesterol(mmol/l)	0.002	0.989
ApoA1(g/l)	0.011	0.943
ApoB(g/l)	0.181	0.223
Triglycerides(mmol/l)	-0.020	0.896
HDL cholesterol(mmol/l)	-0.112	0.453
Fasting blood glucose(mmol/l)	-0.193	0.193
Uric acid(μ mol/l)	-0.079	0.599
CRP(mg/l)	0.351	0.016
CRP(mg/l) in female patients	0.487	0.001

Abstract AB1365 – Figure 1

Conclusions: Elevation of PCSK9 concentrations can be observed in SLE patients, especially in those with LN or atherosclerosis. PCSK9. PCSK9 is probably linked with low-grade inflammation participating in the pathogenesis of atherosclerosis in SLE/LN patients.

REFERENCES:

- [1] Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of aliroc-mab in reducing lipids and cardiovascular events[J]. *N Engl J Med*. 2015 Apr 16;372(16):1489–99.

- [2] McHugh J. Systemic lupus erythematosus: Atherosclerosis confined to patients with nephritis[J]. *Nat Rev Rheumatol*. 2017 Jun;13(6):322.

Acknowledgements: The authors thank Qiulan Li and Hongzhi Gao for the excellent technical assistance.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.1622

AB1366 RADIOISOTOPIC SYNOVIORTHESIS IN THE CONTROL OF REFRACTORY SYNOVITIS IN CASTILLA-LA MANCHA (A REGION OF SPAIN). AN EXPERIENCE OF 10 YEARS

D. Castro Corredor. RHEUMATOLOGY SERVICE, HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL, CIUDAD REAL, Spain

Background: Our hospital is the reference hospital in Nuclear Medicine for the realisation of radioisotopic synoviorthesis for all of Castilla-La Mancha (a region of Spain).

Objectives: To describe the experience in the performance of radioisotopic synoviorthesis in arthritis refractory to other treatments in our hospital.

Methods: Observational, descriptive and cross-sectional study protocolised through the review of the database of radioisotopic synoviorthesis performed between 2007 and 2017. Previous clinical data were collected (age, sex, pathology, previous treatments, previous infiltration and affected joint) and evolutive at 6 months after administering the isotope. An Excel database was created for a frequency analysis with SPSS 21.

Results: 30 radiosynovitis were performed with the most frequent pathologies, in this order: pigmented villonodular synovitis (40%), rheumatoid arthritis (23.3%), spondyloarthritis (13.3%), osteoarthritis (10%) and nonspecific arthritis (6.7%), followed by systemic lupus erythematosus and gout. After 6 months, 56.7% of patients improved compared to 36.7% who remained the same. Likewise, none of them presented complications related to the procedure. A 6.6% of patients were lost to follow-up.

Conclusions: In patients with episodes of recurrent arthritis with associated joint effusion in one or two joints, refractory to systemic treatments, to local infiltrations with corticosteroids and in those patients in whom other treatments may be contraindicated, we must consider the possibility of performing an isotope radiosynoviorthesis, as it is a simple, safe technique with a success rate of more than 50%.

REFERENCES:

- [1] Delbarre f, Cayla, Menkes C. La synoviorthese par les radioisotopes. *Presse Med* 1968; 76:1045
- [2] J. Román Ivorra, J. Chismol Abad, M. Morales Suárez Varela, M. Ureña, J. Ribes Iborra, R. Sopena Monforte. La sinoviortesis radioisotópica en la artritis reumatoide. Estudio de 108 casos. *Revista Española de Medicina Nuclear*. 2000;19(4):275–278.
- [3] Taylor W, Corkill M, Rajapasko C. A retrospective review of yttrium-90 synovectomy in the treatment of knee arthritis. *Br J Rheumatol* 1997; 36:1100–1105.
- [4] Harbert C. Radiocolloid joint therapy in joint diseases. In Habert JC. Edition. Nuclear medicine therapy. New York. Thieme Medical; 1987:169–186.
- [5] Stevenson AC, Bedford J, Hill AGS, Hill H. Chromosome damage in patients who have had intraarticular injections of radioactive gold. *Lancet* 1937b; 2:837839.
- [6] Román J, Chismol J, Morales M, Ureña M, Ribes J, Sopena R. La sinoviortesis radioisotópica en la artritis reumatoide. Estudio de 108 casos. *Rev Esp Med Nucl* 2000; 19:275–278.
- [7] Siegel M, Siegel H, Luck J. Radiosynovectomy's clinical applications and cost effectiveness: A review. *Sem Nucl Med* 1997;27:364–371.
- [8] Mulero J. Sinovectomía quirúrgica y sinovectomía isotópica. *Med Clin (Barc)* 1985; 85:835–837.
- [9] Jones G. Yttrium synovectomy: a meta-analysis of the literature. *Aust NZ J Med* 1993; 23:272–275.
- [10] Heuft-Dorenbosch L, de Vet H, van der Linden S. Yttrium radiosynoviorthesis in the treatment of knee arthritis in rheumatoid arthritis: a systematic review. *Ann Rheum Dis* 2000;59:583–586.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.2785